Company Filing History:
2 out of 2 
2 out of 1,168 Years Active: 2021-2023
Title: Berit Olsen Krogh: Innovator in Neurodegenerative Disease Treatment
Introduction
Berit Olsen Krogh is a notable inventor based in Valby, Denmark. He has made significant contributions to the field of biotechnology, particularly in the development of modified antibodies for treating neurodegenerative diseases. With a total of two patents to his name, Krogh's work is paving the way for innovative therapeutic approaches.
Latest Patents
Krogh's latest patents include a modified anti-PD-L1 antibody and methods for treating neurodegenerative diseases. The specifications disclose modified anti-PD-L1 antibodies that abolish Fc-related effector function while enhancing clearance rates. This innovation maintains therapeutic efficacy for neurodegenerative disease modification. The patents also detail nucleic acid sequences and expression constructs that encode these modified antibodies, along with methods for their production. Furthermore, the specifications outline treatment methods that ensure the antibodies are present in the body for a specific duration, allowing for effective treatment while ensuring they are cleared adequately.
Career Highlights
Throughout his career, Berit Olsen Krogh has worked with prominent companies in the biotechnology sector. Notable among these are Immunobrain Checkpoint, Inc. and Yeda Research and Development Co. Ltd. His work in these organizations has contributed to advancements in the understanding and treatment of neurodegenerative diseases.
Collaborations
Krogh has collaborated with esteemed colleagues, including Ester Yoles and Allan Jensen. These partnerships have fostered a collaborative environment that enhances innovation and research in the field.
Conclusion
Berit Olsen Krogh's contributions to the field of biotechnology, particularly in the development of modified anti-PD-L1 antibodies, highlight his role as an innovator in neurodegenerative disease treatment. His patents and collaborations reflect a commitment to advancing therapeutic options for patients.